Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST -

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to ir@tivichealth.com by November 11.

Conference Call Details:

Toll Free: 877-545-0523

International: 973-528-0016

Access Code: 507355

Webcast Link

https://www.webcaster4.com/Webcast/Page/2865/51524

About Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  225.74
+5.05 (2.29%)
AAPL  276.22
+4.73 (1.74%)
AMD  215.75
+11.97 (5.88%)
BAC  52.11
+0.55 (1.06%)
GOOG  318.05
+18.40 (6.14%)
META  615.94
+21.69 (3.65%)
MSFT  474.99
+2.87 (0.61%)
NVDA  182.16
+3.28 (1.83%)
ORCL  200.45
+1.69 (0.85%)
TSLA  421.03
+29.94 (7.66%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.